Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Neuroblastoma: early-phase trial registry
38 of 98 indexed Neuroblastoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #141 of 28,707 conditions by registered trial count.
98 US clinical trials · 38 currently recruiting · #141 of 28,707 conditions by registered trial count
Neuroblastoma: 98 US clinical trials tracked, 38 recruiting.
Neuroblastoma is the subject of 98 registered US clinical trials on ClinicalTrials.gov, 38 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 78 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 19 of these trials.
Enrollment posture brief
Registry condition neuroblastoma
OPEN 38 | RECR 39% | LATE 6 | EARLY 78 | RANK #141 | SPON 19
Volume-matched condition peers
Nearest open-share peer: Metastatic Urothelial Carcinoma (39% recruiting · 31 trials)
Neuroblastoma lists 38 open slots (39% of 98 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Neuroblastoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Neuroblastoma recruits in line with its size-band peers.
38 of 98 indexed trials (38.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Neuroblastoma research.
Memorial Sloan Kettering Cancer Center accounts for 19 of 98 trials (19.4%). 41 distinct sponsors appear on at least one study for this condition label.
-
Most Neuroblastoma trials plan to enrol fewer than 100 people.
Median target enrolment is 45 among the 95 trials that report a genuine target (sentinel values excluded). 66 of those (69.5%) plan for fewer than 100 participants.
-
Neuroblastoma research is mostly interventional.
89 interventional and 9 observational studies make up this index (90.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
98 total, page 1 of 2
Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
National Cancer Institute (NCI)
NCT01109394
Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
National Cancer Institute (NCI)
NCT01005654
Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
Memorial Sloan Kettering Cancer Center
NCT00588068
Neuroblastoma Biology Study
New Approaches to Neuroblastoma Therapy Consortium
NCT01587300
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Children's Oncology Group
NCT03126916
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
Giselle Sholler
NCT02559778
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
National Cancer Institute (NCI)
NCT06172296
Neuroblastoma Maintenance Therapy Trial
Giselle Sholler
NCT02679144
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Milton S. Hershey Medical Center
NCT06465199
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
Memorial Sloan Kettering Cancer Center
NCT04936529
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Memorial Sloan Kettering Cancer Center
NCT00107289
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Children's Oncology Group
NCT04851119
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Giselle Sholler
NCT04301843
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
Y-mAbs Therapeutics
NCT03363373
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Milton S. Hershey Medical Center
NCT06541262
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
Giselle Sholler
NCT06540963
A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
Memorial Sloan Kettering Cancer Center
NCT06057948
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Giselle Sholler
NCT05489887
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Merck Sharp & Dohme
NCT06395103
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
Nationwide Children's Hospital
NCT05135975
Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
Dana-Farber Cancer Institute
NCT06831552
GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma
Baylor College of Medicine
NCT03294954
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
New Approaches to Neuroblastoma Therapy Consortium
NCT06450041
MCT for the Harvard/UCSF ROBIN Center
Brigham and Women's Hospital
NCT06000787
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
Memorial Sloan Kettering Cancer Center
NCT06528496
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
Crystal Mackall, MD
NCT06500819
Biomarkers of Resiliency In Childhood Cancer Surgery
Mayo Clinic
NCT06674811
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
National Cancer Institute (NCI)
NCT06995872
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
St. Jude Children's Research Hospital
NCT04897321
Phase II Study of Proton Radiation Therapy for Neuroblastoma
Massachusetts General Hospital
NCT02112617
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
University of Florida
NCT06625190
Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma
Emory University
NCT05400603
A Study of Avutometinib for People With Solid Tumor Cancers
Memorial Sloan Kettering Cancer Center
NCT06104488
Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
Valent Technologies
NCT04337177
Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
Children's National Research Institute
NCT07172958
Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma
UNC Lineberger Comprehensive Cancer Center
NCT03721068
Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
Steven DuBois, MD
NCT07027748
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
Masonic Cancer Center, University of Minnesota
NCT02605421
Genomic Structural Variation in Cancer Susceptibility
Memorial Sloan Kettering Cancer Center
NCT00996710
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
Children's Oncology Group
NCT02176967
Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
NCT00911560
Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
NCT01757626
Therapy for Children With Advanced Stage Neuroblastoma
St. Jude Children's Research Hospital
NCT01857934
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
Pfizer
NCT03709680
Neuroblastoma Precision Trial
New Approaches to Neuroblastoma Therapy Consortium
NCT02868268
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
Eli Lilly and Company
NCT04106219
Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01
Seattle Children's Hospital
NCT02311621
Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma
University Hospital Southampton NHS Foundation Trust
NCT02914405
Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)
Children's Oncology Group
NCT04385277
Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas
Cellectar Biosciences
NCT03478462
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 48 |
| Phase 2 | 30 |
| Phase 3 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Neuroblastoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Neuroblastoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Neuroblastoma page
98 registered trials, 38 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 38 Neuroblastoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Neuroblastoma trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neuroblastoma condition card totals 98 registered trials; most-linked intervention Cyclophosphamide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.